Capmatinib in MET Exon 14-Mutated or MET-Amplified Non-Small-Cell Lung Cancer

Wolf, J; Seto, T; Han, JY; Reguart, N; Garon, EB; Groen, HJM; Tan, DSW; Hida, T; de Jonge, M; Orlov, SV; Smit, EF; Souquet, PJ; Vansteenkiste, J; Hochmair, M; Felip, E; Nishio, M; Thomas, M; Ohashi, K; Toyozawa, R; Overbeck, TR; de Marinis, F; Kim, TM; Laack, E; Robeva, A; Le Mouhaer, S; Waldron-Lynch, M; Sankaran, B; Balbin, OA; Cui, XM; Giovannini, M; Akimov, M; Heist, RS

Wolf, J (corresponding author), Univ Hosp Cologne, Ctr Integrated Oncol, Dept Internal Med 1, D-50924 Cologne, Germany.

NEW ENGLAND JOURNAL OF MEDICINE, 2020; 383 (10): 944

Abstract

BACKGROUND Among patients with non-small-cell lung cancer (NSCLC),METexon 14 skipping mutations occur in 3 to 4% andMETamplifications occur in 1 to 6%......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索